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Hepatoma cells are known to be highly resistant to chemotherapy. Previously, we have found differential Taxol resistance in human
and murine hepatoma cells. The aim of this study was to examine the effect of a multidrug resistance inhibitor, cyclosporin A in
combination with Taxol on hepatoma in vitro and in vivo, and to identify the possible mechanism involved in Taxol resistance.
Simultaneous treatment of cyclosporin A (0–10mM) and Taxol (0.1mM) inhibited cell growth in vitro. Cyclosporin A interfered with
Taxol (0.1mM)-induced AKT activation and BAD phosphorylation. Cyclosporin A combined with Taxol treatment augments caspase-
9, -3 activation and loss of mitochondrial membrane potential in HepG2 cells. PI3 kinase inhibitor, wortmannin, or a dominant-
negative AKT1 expression vector treatment partially enhanced Taxol-induced apoptosis indicating that PI3 kinase-AKT pathway was
involved in Taxol-resistance pathway. Moreover, combination treatment reduced tumour growth in SCID and C57BL/6 mice as
compared to either Taxol or cyclosporin A treatment. Our results indicate that the combination of cyclosporin A and Taxol is
effective in the reversal of Taxol resistance through the inhibition of PI3 kinase-AKT1 pathway.
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Hepatocellular carcinoma (HCC) is highly resistant to chemother-
apy and the curative approach is surgical resection. However,
tumour location and number as well as frequent recurrence rate
limited the survival of patients with HCC (Nagasue et al, 1993;
Shimada et al, 1996; Nonami et al, 1997). Thus, preoperative or
postoperative adjuvant chemotherapy could be used to improve
the surgical results (Nagasue et al, 1993; Izumi et al, 1994; Tanaka
et al, 1999). Hepatocellular carcinoma originates from the liver,
which is responsible for the detoxification of exogenous and
endogenous chemicals. High level of phase I and phase II enzyme
activity as well as membrane transporter system (multidrug
resistance, MDR and multidrug resistance-related protein, MRP)
were documented in the liver (Cavalieri et al, 1997) and hepatoma
cells (Kool et al, 1997; Lin et al, 1999). Moreover, HCC grows as
solid spheroid-like architecture leading to less drug uptake. Taken
together, the intrinsic factors and microenvironment are two
important obstacles for chemotherapeutic treatment of patients
with HCC.
Taxol, one of the antimicrotubule chemotherapeutic drugs, has
been reported to be effective in the treatment of many tumours
including ovarian, breast and lung cancers (Chabner, 1991;
Rowinsky and Donehower, 1991; Slichenmyer and Von Hoff,
1991) but not in HCC (Chao et al, 1998). The well-established
action mechanism of Taxol in the treatment of cancer is based on
stabilisation of microtubules in tumour cells and induction of
apoptosis. In addition, several signal transduction pathways such
as Raf, JNK (Torres and Horwitz, 1998; Wang et al, 2000) and
specific cell cycle phase (Lin et al, 1998) have been indicated to be
involved in Taxol-elicited apoptotic responses. Moreover, expres-
sion of oncogenes or drug resistance factors as well as decoy
receptors induction could account for the low response rate after
chemotherapy in patients with HCC (Chao et al, 1998; Yamanaka
et al, 2000), including Taxol treatment.
Taxol is known to be metabolised (Harris et al, 1994b) in the
liver and inactivated (Harris et al, 1994a) by cytochrome P450 3A4.
Cyclosporin A is also metabolised by cytochrome P450 3A in the
liver (Villeneuve et al, 2000) and has been found to block the
function of MDR (Twentyman et al, 1987). A recent report further
showed that cyclosporin A modulated the absorption of oral
administration of Taxol and increased the plasma concentration of
Taxol in patients with solid tumours (Meerum Terwogt et al,
1999). It was suggested that cyclosporin A modulated the function
of MDR that led to increased Taxol absorption in the gastro-
intestinal tract. Whether a combination of cyclosporin A and Taxol
will induce Taxol-resistant hepatoma cells to respond to Taxol is
worth investigating.
In a previous study, we have found that HepG2 and HA22T/
VGH hepatoma cells were highly resistant to Taxol treatment,
while Hepa 1-6 and Hep3B cells were relatively more sensitive to
Taxol (Lin et al, 2000). The objective of this study was to
investigate whether cyclosporin A enhanced the responses of
Taxol-resistant hepatoma cells to Taxol treatment in vitro and in
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svivo. We show that reversal of Taxol resistance in hepatoma cells
was observed. In addition, we show that the PI3 kinase
(phosphoinositide 3-kinase)-AKT1 signalling pathway is involved
in Taxol resistance.
MATERIALS AND METHODS
Cell culture, transfection and treatment
Human hepatoma cell lines, Hep3B, HepG2, HA22T/VGH, and
murine hepatoma cell line, Hepa 1-6, were cultured in DMEM
(GIBCO, BRL NY, USA) containing 10% fetal bovine serum
(Hyclone, UT, USA), 0. 01mgml
1 gentamycin and 0.1mM
nonessential amino acid. Cells were grown in a CO2 incubator at
371C, with 5% CO2 and 95% filtered air. For transient transfection,
HepG2 cells (310
5) were cultured in 35-mm dish overnight and
transient transfected with pUSEamo(+) vector or dominant-
negative AKT1 expression vector (Upstate Biotechnology, NY,
USA) by using LIPOFECTAMINE PLUS reagents (GIBCO, BRL NY,
USA) according to the manufacturer’s instructions. Hepatoma cells
were treated with Taxol (Biomol PA, USA) combined with
cyclosporin A (Sigma MO, USA) or wortmannin at indicated
concentrations. Taxol was dissolved in DMSO as stock solution, the
final concentration of DMSO was o0.1% in media. For in vivo
experiments, Taxol was dissolved in DMSO (5mgml
1) as stock and
diluted with phosphate-buffered saline (PBS) to final concentration.
Viability assay
Cells were cultured in a 96-well cell culture cluster (COSTAR NY,
USA) at a density of 410
4 cellsml
1. After drug treatment for
24–72h, the medium was discarded and replaced with an equal
volume (100ml) of fresh medium containing MTT (0.456mgml
1;
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide)
and incubated for 1.5h at 371C. The medium was discarded. Cells
were then combined with 100ml DMSO. Cell viability was
determined according to the colorimetric comparison by reading
OD values from a microplate reader (SPECTRA MAX 250 Molecular
Devices, CA, USA) at an absorption wavelength of 570nm.
Assay of caspase activity
Caspase activity was determined as described previously (Lin et al,
2001). Briefly, cell pellets were collected, washed with PBS and
extracted with lysis buffer (20mM Tris buffer (pH 7.5), 1mM
EDTA, 100mM phenylmethylsulphonyl fluoride, aprotonin
(2mgml
1), pepstatin (2mgml
1) and leupeptin (2mgml
1)). An
aliquot of total protein was incubated with reaction buffer (50mM
HEPES, 10% sucrose, 0.1% CHAPS, pH 7.5), dithiothreitol
(50.5mM) and substrates (YVAD-pNA, DEVD-pNA, IETD-pNA
or LEHD-pNA for caspase-1, -3, -8 or –9, respectively). Caspase
activity was determined according to the colorimetric comparison
by reading OD values from a microplate reader at an absorption
wavelength of 405nm. Data are presented as fold of increase as
compared to respective control groups.
Mitochondria membrane potential measurement
Treated cells were harvested and stained with JC-1 (0.2mgml
1).
(Molecular Probe OR, USA) for 10min in Medium 199 (GIBCO,
BRL NY, USA) at 371C. The loss of mitochondria membrane
potential was measured by flow cytometry for the decreased red
fluorescence.
Western blot analysis
Total proteins were extracted with lysis buffer (20mM Tris buffer





1)). Protein quantity was measured by Bradford assay
and an equal quantity of total protein (15mg) was applied on 10 or
12.5% SDS – PAGE. Equal loading of total protein was determined
by electrophoresis prior to staining with GelCode
s (Pierce IL,
USA) for visualisation. After protein transfer onto nitrocellulose
membrane, specific protein expression level was measured by
using antibodies for AKT1 (Upstate, NY, USA), phosphorylated
AKT1 (Upstate, NY, USA), BAD (Santa Cruz CA, USA),
phosphorylated BAD (Upstate, NY, USA), PTEN (Santa Cruz CA,
USA) and procaspase 3 (IMGENEX CA, USA), respectively,
followed by enhanced chemiluminescence detection.
Flow cytometry
Cells (10000) were analysed on a Becton Dickinson FACSCalibur
flow cytometer (San Jose, CA, USA) using an argon-ion laser
(15mW) with an incident beam at 488nm. For the green or red JC-
1 fluorescence, signals were detected by collection through a 530 or
585nm filter, respectively.
Animal study
Male SCID mice and C57BL/6 mice with body weight of 20–23g
were obtained from the National Taiwan University and National
Laboratory Animal Breeding and Research Center of National
Science Council, respectively. SCID mice were maintained in
isolated cages with filter bonnet in a room with 12-h dark and light
cycle. For experiments, Hepa 1-6 (510
6 cells) cells were
inoculated s.c. in 7–8-week old SCID or C57BL/6 mice 3 days
prior to treatment with cyclosporine A and Taxol. Tumour cells
were injected subcutaneously at day 0. After 3 days (day 3), mice
with detectable small nodule (0.20.2cm
2 in diameter) were
enrolled and then cyclosporin A (5 or 6.67mgkg
1) and/or Taxol
(2 or 2.68mgkg
1) administered intraperitoneally at days 3, 4, 9,
10 for SCID mice or days 3, 4, 10, 11, 16, 17, 22, 23, 29, 30 for
C57BL/6 mice.
Statistics
In vitro or in vivo data were expressed as the mean7s.e. of mean
from indicated sample size. Differences between the means were
analysed by one-way analysis of variance or Student’s t-test.
Statistical significance was considered when Po0.05.
RESULTS
Cyclosporin A enhanced Taxol-induced cytotoxicity in
hepatoma cells
We investigated the combination effect of cyclosporin A and Taxol
on three human hepatoma cell lines (Hep3B, HepG2 and HA22T/
VGH) and one murine hepatoma cell line (Hepa 1-6) (Figure 1A).
After cyclosporin A combined with Taxol treatment for 24 and
72h, we found that cyclosporin A treatment alone resulted in
decreased cell viability in Hep3B and Hepa 1-6 cells at 72h after
treatment. A dose-dependent decrease of cell viability was
observed after cyclosporin A treatment. No significant decrease
in cell viability was observed in HepG2 and HA22T/VGH cells after
cyclosporin A treatment. These four hepatoma cell lines showed
similar enhanced cytotoxic effect at 10mM cyclosporin A combined
with 0.1mM Taxol treatment for 72h. Therefore, we examined
another immunosuppressant, FK 506, on the combination effect
with Taxol. Figure 1B shows that no enhanced cytotoxic effect was
observed in Hep3B, Hepa 1-6 and HA22T/VGH cells treated for 24
and 72h. However, a partial effect was observed in HepG2 cells at
10mM of FK506 combined with 0.1mM Taxol treatment for 72h.
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Either cyclosporin A or Taxol alone treatment had no significant
effect on caspase-1, -3, and -8 activation in HepG2 and HA22T/
VGH cells. In combination treatment of HepG2 cells for 24h, the
initially responsive dose of cyclosporin A was 1mM, which
enhanced Taxol-induced caspase-3 activation, but not that of
caspase-1 and -8. Identical results were observed at 10mM
cyclosporin A combined with 0.1mM Taxol treatment in HA22T/
VGH cells. For Hep3B and Hepa 1-6 cells, Taxol alone induced
caspase-3 activation and no apparent augmentation was found
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Figure 1 Effect of Taxol (0.1mM) and cyclosporin A (1–10mM)( A), or Taxol (0.1mM) and FK506 (0.01–10mM)( B) on cell viability of hepatoma cells.
Data are expressed as mean7s.e. of mean from duplicate samples of three to five separate experiments. *indicates Po0.05 as compared with respective
control group.
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sorder to determine the effect of cyclosporin A and Taxol
combination treatment on the cascade of caspases activation, we
investigated the membrane-derived signalling pathway, caspase-8
and mitochondria-derived signalling pathway, caspase-9, as well as
caspase-1 and -3 activities in HepG2 cells. Figure 2B shows that
activation of caspase-3 and -9 was observed within 11–24-h
interval while no apparent changes was found between 1 and 10h
(data not shown). Moreover, caspase-1 and -8 were not
significantly activated after combination treatment, indicating
the specificity of caspase activation.
Drug-induced loss of mitochondrial membrane potential
Since initiator caspase-9 and executioner caspase-3 were activated
after combination treatment, we further investigated whether
caspase-9 activation was the result of mitochondria-mediated
signals. It has been reported that loss of mitochondrial membrane
potential elicited caspase-9-dependent apoptosis (Green and Reed,
1998). Thus, we utilised JC-1 as a specific probe for the
determination of mitochondrial membrane potential. When the
mitochondria maintain membrane potential, JC-1 (green fluores-
cence) forms the J-aggregates (red fluorescence). If mitochondrial
membrane is depolarised, red fluorescence is reduced and
eventually green fluorescence increased. As shown in Figure 3, a
combination treatment for 2–24h enhanced the loss of mitochon-
drial membrane potential in HepG2 cells as compared to the Taxol
or cyclosporin A alone treatment groups. In an attempt to analyse
the time-course response of changes in mitochondrial membrane
potential, we found that Taxol-induced a biphasic effect within
24h. However, cyclosporin A and Taxol combination treatment led
to inhibition of the Taxol-induced biphasic response and enhanced
mitochondrial depolarisation.
Hep  3B
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Figure 2 Effect of combined cyclosporin A (1–10mM) and Taxol (0.1mM) treatment on caspase-1, -3 and -8 activities in hepatoma cells at 24h (A). The
time-course response on caspase-1, -3, -8 and -9 activities after treatment of hepatoma cells with cyclosporin A (10mM) and Taxol (0.1mM)( B). Data are
expressed as mean7s.e. of mean from duplicate samples of two to three separate experiments.
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sEffect of cyclosporin A and Taxol on signal transduction
Since the PI3-kinase-AKT pathway has been reported to be
involved in cell survival response, we examined this pathway in
cyclosporin A combined with Taxol treatment in HepG2 cells.
Figure 4 shows that the level of phosphorylated active AKT1 (Ser
473) was increased after Taxol treatment and this increase was
blocked by cyclosporin A combination treatment with Taxol
(Figure 4). In addition, the AKT1 downstream protein, BAD, was
phosphorylated by Taxol treatment and the phosphorylated level
was reduced after combination treatment of Taxol and cyclosporin
A. Next, we analysed the expression of a phosphatase, PTEN,
which is reported to be responsible for the inactivation of AKT1
protein. We found that no change was observed at 4h after drug
treatment. However, PTEN expression was increased at 7h after
cyclosporin A and Taxol combination treatment. Moreover, we
have found that the procaspase-3 level was reduced after
combination treatment, which was consistent with the caspase-3
activation (Figure 2). In order to clarify the role of PI-3 kinase in
Taxol-induced responses, we evaluated the cell viability by using a
PI-3 kinase inhibitor, wortmannin (10mM), combined with Taxol.
Table 1 shows that wortmannin enhanced the Taxol-induced
cytotoxicity in four hepatoma cell lines. Further analysis of the
caspase-3 activity showed that wortmannin-combined Taxol
treatment significantly augmented caspase-3 activity as compared
with either wortmannin or Taxol alone treatment (Figure 5A). To
examine the role of AKT1 in Taxol-induced responses in HepG2
cells, a dominant-negative AKT1 expression vector was used. As


























































cyclosporinA (CA, 10 M)
Tx + CA
Figure 3 Percent changes in mitochondrial membrane potential after
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32 h after treatment
Figure 4 Western blot analysis of phospho-AKT1, AKT1, PTEN, phospho-BAD, BAD and procaspase-3 expression in HepG2 cells treated with
cyclosporin A (CA, 10mM) and/or Taxol (Tx, 0.1mM).
Table 1 Cell viability of hepatoma cell lines after wortmannin (10mM)
and Taxol (0.01 or 0.1mM) treatment for 72h





a 80.6571.32 63.3970.60 57.4271.97
Hepa 1-6
a 74.3873.16 45.3271.61 37.3273.60
HepG2
a 74.7276.82 60.1673.48 50.6572.50
HepG2
c 74.7276.82 49.7172.80 38.9375.30
aThe concentration of Taxol used in these cell lines was 0.01mM.
bData are expressed
as percentage of control.
cThe concentration of Taxol used was 0.1mM.
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sshown in Figure 5B, transient transfection of a dominant-negative
AKT1 in HepG2 cells had a similar effect on the enhancement of
Taxol-induced caspase-3 activity by wortmannin.
Tumour growth inhibition in vivo
We evaluated the effect of cyclosporin A and Taxol combination
treatment in SCID mice inoculated with Hepa 1-6 cells. To simulate
the microenvironment of a solid tumour responding to che-
motherapy, we injected Hepa 1-6 cells subcutaneously and
produced a 0.20.2cm
2 (in diameter) small nodule in 3 days
for the following studies. In a first set of experiments, SCID mice
bearing Hepa 1-6 tumour were treated with combined cyclosporin
A (6.67 or 5mgkg
1) and/or Taxol (2.68 or 2mgkg
1) twice a
week for 3 weeks. Figure 6A shows that cyclosporin A
(6.67mgkg
1) and Taxol (2.68mgkg
1) treatment alone did not
inhibit tumour growth. Similar results were observed with lower
doses of cyclosporin A (5mgkg
1) and Taxol (2mgkg
1) (data not
shown). In contrast, combination treatment resulted in significant
growth inhibition of Hepa 1-6 tumour. The combination of a lower
dose of cyclosporin A (5mgkg
1) and Taxol (2mgkg
1) showed a
slightly better response than that of the higher dose of cyclosporin
A (6.67mgkg
1) and Taxol (2.68mgkg
1) at 20 days after
treatment. To confirm this observation, we performed a second
experiment using an immune competent mouse C57BL/6 mouse
model. Figure 6B shows that no significant growth inhibition of
Hepa 1-6 tumour was observed in mice receiving either a lower
dose of cyclosporin A (5mgkg
1) or Taxol (2mgkg
1). In
contrast, significant tumour growth inhibition (Po0.05) was
observed in mice receiving combination treatment. The growth
inhibition was not the result of drug-induced toxicity because no
loss of body weight was observed as compared with vehicle group
(data not shown).
DISCUSSION
Hepatocellular carcinoma is a solid tumour that is well known for
poor response to chemotherapy. In a clinical trial using Taxol to
treat 20 patients with HCC, no complete or partial response was
observed (Chao et al, 1998). Frankel et al have indicated that
cancer cells grown as spheroids showed decreased Taxol-induced
cytotoxicity (Frankel et al, 1997). This corresponded well with our
observation that no significant tumour regression was found after
Taxol treatment (Figure 6). We have clearly shown that
cyclosporin A and Taxol combination treatment resulted in the
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Figure 5 (A) Caspase-3 activity in HepG2 cells after wortmannin (10mM) and/or Taxol (0.1mM) treatment for 24h. *Po0.001 as compared with
wortmannin alone treatment; #Po0.01 as compared with Taxol alone treatment, (B) Effect of a dominant-negative AKT1 expression vector (dn AKT) and
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Figure 6 Growth inhibition of Hepa 1-6 tumours in SCID (A) and
C57BL/6 (B) mice after treatment with cyclosporin A (CA) and/or Taxol
(Tx). Cyclosporin A was given at two doses (CA (H): 6.67mgkg
1; CA (L):
5mgkg
1). The dose of Taxol was Tx (H): 2.68mgkg
1 and Tx (L):
2mgkg
1, respectively. Each point represents average from five to seven
mice. The detailed procedures of animal studies were described in Materials
and Methods.
#Po0.05; *Po0.01 compared with DMSO control.
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ssystem (Figure 1) but also in an in vivo solid hepatoma model
(Figure 6).
Clinically, venous invasion, multiple type and diffuse type of
HCC limited surgical resection. Preoperative chemotherapy could
provide an adjuvant therapy to facilitate reducing tumour size or
number, and subsequently perform curative resection. Postopera-
tively, HCC recurrence in residual liver is a major problem in
patients 1 year after surgical resection. It is estimated that 90% of
HCC recurrence grows as multiple and nodule type, which not only
decrease tumour response to chemotherapy but also limit repeated
resection (Nagasue et al, 1993). Although Taxol-based therapy in
patients with breast cancer showed efficient responses, Chao et al
(1998) have found that Taxol failed to benefit patients with
unresectable HCC. The observed poor response of these patients to
Taxol corresponded well with our in vitro results, which showed
that hepatoma cells had a different degree of resistance to Taxol
(Lin et al, 1999, 2000). These results further suggest that the Taxol
resistance in HCC may involve poor uptake of Taxol because of the
barrier in solid tumour as well as the intrinsic factors that regulate
the metabolism of Taxol and cellular response to Taxol. The
reversal of Taxol resistance in hepatoma cells suggests that
combination of cyclosporin A and Taxol has potential for adjuvant
therapy of HCC patients.
Identification of cellular targets of various drugs is important for
the development of mechanism-based therapies. In this study, we
have found that AKT1 was activated in Taxol-treated hepatoma
cells. In addition, it was accompanied with phosphorylated
downstream target protein – BAD (Figure 4). It has been reported
that cytoplasmic phosphorylated BAD is involved in the preven-
tion of mitochondria-derived apoptosis (Datta et al, 1997).
Moreover, Cardone et al (1998) reported that AKT directly
phosphorylated and inactivated caspase-9. Caspase-9 was found
to be responsible for caspase-3 activation. Subsequent caspase-3
activation was required for a positive feedback loop in maintaining
the status of loss of mitochondrial membrane potential (Heerdt
et al, 1999). In this study, we have found that Taxol induced AKT1
activation in Taxol-resistant hepatoma cells (Figure 4). In contrast,
AKT activated by HGF partially inhibited the Taxol-induced
apoptosis in Taxol-responsive human U373 glioblastoma cells
(Bowers et al, 2000). It is clear that initially Taxol induced loss of
mitochondrial membrane potential (Figure 3) that was followed by
AKT1 activation (Figure 4). Caspase-9 was possibly inhibited in
part by AKT1 activation and blocked a positive feedback loop for
sustained caspase-3 activation as well as sustaining loss of
mitochondrial membrane potential. Both wortmannin and domi-
nant-negative AKT1 expression vector partially reversed Taxol
resistance in hepatoma cells (Figure 5), which further supports that
AKT may coordinate the antiapoptotic activities and resulted in
drug-resistant responses in hepatoma cells.
Another important intrinsic factor for Taxol resistance is the
increased expression of MDR in hepatoma cells. Using rhodamine
123 fluorescence retention method (Lin et al, 1999) to evaluate the
effect of cyclosporin A on the MDR1 transporter activity, we have
found that cyclosporin A (1mM) had no effect on the function of
MDR1 in HepG2 cells (data not shown). Therefore, the effect of
cyclosporin A on the reversal of Taxol resistance in hepatoma cells
most likely resulted from the modulation of the PI3 kinase-AKT1
signalling pathway rather than from the regulation of the MDR
transporter system of hepatoma cells.
Finally, we conclude that cyclosporin A combined with Taxol
treatment is effective against hepatoma growth in vitro and in vivo.
The key to reversal of Taxol resistance may lie in the modulation of
cellular signal transduction molecules such as AKT1 and PI3
kinase. Our results provided a mechanism-based research in
combination treatment of HCC. Cyclosporin A and Taxol are
clinically available drugs, the combination of these two drugs for
pre- or postoperative adjuvant chemotherapy is worthy of clinical
trial in patients with HCC.
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